Related Experiment Videos
Cilostazol in diabetic neuropathy: premature farewell or new beginning?
1Outpatient Clinic of the Diabetic Foot, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece. papanasnikos@yahoo.gr
Abstract:
Peripheral neuropathy remains a major chronic complication of diabetes mellitus. Its pathogenesis mainly involves chronic glucose toxicity and nerve ischemia. Preclinical studies have shown that cilostazol, a reversible selective inhibitor of phosphodiesterase-3A with antiplatelet, antithrombotic, and vasodilatory properties, exerts beneficial effects on nerve function in experimental diabetes. Clinical data, however, is sparse. Two recent randomized placebo-controlled clinical trials showed that cilostazol did not improve diabetic neuropathy in humans. Hence, more data is needed to confirm or refute the poor clinical efficacy of cilostazol. Importantly, future studies should include larger patient series, provide longer follow-up data, and employ more accurate diagnostic tools.
Insights
Cilostazol shows promise for diabetic neuropathy in preclinical studies, but human trials are inconclusive. Further research with larger patient groups and better diagnostic tools is needed to determine its clinical effectiveness.
Area of Science:
- Neurology
- Endocrinology
- Pharmacology
Background:
- Diabetic peripheral neuropathy is a significant chronic complication of diabetes mellitus.
- Pathogenesis involves chronic hyperglycemia and nerve ischemia.
- Preclinical studies suggest cilostazol may benefit nerve function in experimental diabetes.
Purpose of the Study:
- To evaluate the clinical efficacy of cilostazol in treating diabetic neuropathy.
- To address the sparse clinical data and conflicting trial results.
Main Methods:
- Review of preclinical findings and recent randomized placebo-controlled clinical trials.
- Analysis of existing clinical data on cilostazol for diabetic neuropathy.
Main Results:
- Preclinical studies indicated positive effects of cilostazol on nerve function.
- Two recent clinical trials demonstrated no significant improvement in human diabetic neuropathy with cilostazol.
- Current clinical evidence is limited and inconclusive.
Conclusions:
- Cilostazol's clinical efficacy for diabetic neuropathy remains uncertain.
- Further large-scale, long-term clinical trials with advanced diagnostic methods are required.
- Confirming or refuting cilostazol's poor clinical efficacy necessitates more robust data.
Related Concept Videos
Diabetic Neuropathy
Diabetic Foot Ulcer
Diabetic Nephropathy
Peripheral Artery Disease III: Interprofessional Care
Diabetic Retinopathy
Diabetes Mellitus: Introduction